Discovery and development of HIV-protease inhibitors

Results: 12



#Item
1June 17, 2009   Chemicals Targeting an HIV‐1 Nef/Host Cell Kinase Complex as Novel Anti‐ Retroviral Compounds    Damilola A. Adepegba, Department of Natural Sciences, University of Maryland 

June 17, 2009  Chemicals Targeting an HIV‐1 Nef/Host Cell Kinase Complex as Novel Anti‐ Retroviral Compounds    Damilola A. Adepegba, Department of Natural Sciences, University of Maryland 

Add to Reading List

Source URL: www.csb.pitt.edu

Language: English - Date: 2013-11-27 16:23:21
2The Battle Against Microbial Pathogens: Basic Science, Technological Advances and Educational Programs A. Méndez-Vilas (Ed.) Protease Inhibitors as Antimicrobials A. Ahmad1 and S. Fatima2 1

The Battle Against Microbial Pathogens: Basic Science, Technological Advances and Educational Programs A. Méndez-Vilas (Ed.) Protease Inhibitors as Antimicrobials A. Ahmad1 and S. Fatima2 1

Add to Reading List

Source URL: www.formatex.info

Language: English - Date: 2015-04-08 02:59:18
3For Immediate Release  Enanta Pharmaceuticals Announces Submission of EU Marketing Authorization Applications to the European Medicines Agency for All-Oral, Interferon-Free Hepatitis C Regimen Containing ABT-450 Submissi

For Immediate Release Enanta Pharmaceuticals Announces Submission of EU Marketing Authorization Applications to the European Medicines Agency for All-Oral, Interferon-Free Hepatitis C Regimen Containing ABT-450 Submissi

Add to Reading List

Source URL: hbmpartners.com

Language: English - Date: 2014-06-23 10:06:06
4____________________________________________________________________________________ Date: 3/02  Information, Inspiration and Advocacy for People Living with HIV/AIDS

____________________________________________________________________________________ Date: 3/02 Information, Inspiration and Advocacy for People Living with HIV/AIDS

Add to Reading List

Source URL: img.thebody.com

Language: English - Date: 2006-09-17 23:25:35
5Enanta Pharmaceuticals Announces New Drug Application Submission to the U.S. FDA for All-Oral, Interferon-Free Hepatitis C Regimen April 22, 2014 8:53 AM ET Filing Triggers Milestone Payment to Enanta ● ●

Enanta Pharmaceuticals Announces New Drug Application Submission to the U.S. FDA for All-Oral, Interferon-Free Hepatitis C Regimen April 22, 2014 8:53 AM ET Filing Triggers Milestone Payment to Enanta ● ●

Add to Reading List

Source URL: hbmpartners.com

Language: English - Date: 2014-06-23 10:05:35
6

PDF Document

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2001-10-30 12:45:56
7A Reverse Binding Motif That Contributes to Specific Protease Inhibition by Antibodies

A Reverse Binding Motif That Contributes to Specific Protease Inhibition by Antibodies

Add to Reading List

Source URL: mpec.ucsf.edu

Language: English - Date: 2012-07-14 18:36:39
8The Role of STD Detection and Treatment

The Role of STD Detection and Treatment

Add to Reading List

Source URL: dhss.delaware.gov

Language: English - Date: 2013-09-17 13:57:46
9AIDS InfoNet  www.aidsinfonet.org Fact Sheet Number 106

AIDS InfoNet www.aidsinfonet.org Fact Sheet Number 106

Add to Reading List

Source URL: aidsinfonet.org

Language: English - Date: 2014-04-21 15:36:33
10[removed]Dear Dr. Letter – Rifampin and Saquinavir Drug Interaction

[removed]Dear Dr. Letter – Rifampin and Saquinavir Drug Interaction

Add to Reading List

Source URL: www.fda.gov

Language: English